Biblio Discovery — Demo Discovery Service

8 results for "Cameron Gofton"

Showing 1–8 · 0.43 seconds · RSS

  1. Journal Article

    Dawn of an era of effective treatments for MAFLD

    Cameron Gofton; Jacob George

    Portal Hypertension & Cirrhosis, Vol. 3 No. 4 · 2024 · English · DOAJ Scopus

    Abstract Fatty liver disease is a commonly occurring disease resulting in hepatic and extrahepatic complications. To date, there have been few available treatments beyond conventional lifestyle modification. While lifestyle modifications resulting in weight loss >10% have shown to be beneficial for…

  2. Journal Article Full text

    MAFLD: How is it different from NAFLD?

    Cameron Gofton; Yadhavan Upendran; Ming‐Hua Zheng et al.

    Clinical and Molecular Hepatology · 2022 · English · OpenAlex Scopus

    "Metabolic dysfunction-associated fatty liver disease (MAFLD)" is the term suggested in 2020 to refer to fatty liver disease related to systemic metabolic dysregulation. The name change from nonalcoholic fatty liver disease (NAFLD) to MAFLD comes with a simple set of criteria to enable easy…

    Also available at: DOAJ

  3. Journal Article

    A Rare, Atypical Presentation of Decompensated Cirrhosis: Isolated Transudative Hepatic Chylothorax Without Ascites

    Michael Yulong Wu; Rhian Aghajani; Sophie Timmins et al.

    Case Reports in Hepatology, Vol. 2025 · 2025 · English · DOAJ

    Hepatic hydrothorax is an uncommon presentation of decompensated liver cirrhosis and usually presents after other complications of portal hypertension such as ascites. We report the case of a 73-year-old female with autoimmune hepatitis (AIH) treated with budesonide, presenting with a right-sided…

  4. Journal Article Full text

    Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis

    Harry Crane; Guy D. Eslick; Cameron Gofton et al.

    Clinical and Molecular Hepatology, Vol. 30 No. 3 · 2024 · English · DOAJ Scopus

    Background/Aims The global proportion of hepatocellular carcinoma (HCC) attributable to metabolic dysfunction-associated fatty liver disease (MAFLD) is unclear. The MAFLD diagnostic criteria allows objective diagnosis in the presence of steatosis plus defined markers of metabolic dysfunction…

  5. Journal Article

    Efficacy of albumin use in decompensated cirrhosis and real‐world adoption in Australia

    Eric Kalo; Scott Read; Asma Baig et al.

    JGH Open, Vol. 8 No. 9 · 2024 · English · DOAJ Scopus

    Abstract The current treatment approach to patients with liver cirrhosis relies on the individual management of complications. Consequently, there is an unmet need for an overall therapeutic strategy for primary and secondary prevention of complications. The clinical potential of long‐term albumin…

  6. Journal Article

    Implementing palliative care in hepatocellular carcinoma ambulatory clinics—study protocol for Accelerated translational research in PRImary liver CAncer (APRICA) randomised controlled palliative care trial

    Cameron Gofton; Anna Di Bartolomeo; Rose Boutros et al.

    Trials, Vol. 25 No. 1 · 2024 · English · DOAJ Scopus

    Abstract Background Integration of symptom and palliative care for people with advanced cancer is established in many tumour types, but its role in people with hepatocellular carcinoma (HCC) has not been clearly defined. This study aims to evaluate the clinical and cost effectiveness of an…

  7. Journal Article

    Delphi survey to explore core curriculum for training the next generation of hepatologists

    Xinyi Xu; Yu Shi; Frank Tacke et al.

    JHEP Reports, Vol. 8 No. 9 · 2026 · English · DOAJ Scopus

    Background & Aims: Hepatology is experiencing major shifts in disease etiologies and is raising demand for multidisciplinary care. However, a globally harmonized framework defining core training content remains lacking. We aimed to develop a globally informed expert consensus framework for the…